Matthew Abernethy - Neurocrine Biosciences Chief Officer
| NBIX Stock | USD 125.65 0.65 0.52% |
Executive
Mr. Matthew C. Abernethy is Chief Financial Officer of the Company. Abernethy joins the Company from Zimmer Biomet, where he held various positions over the past nine years including Vice President, Investor Relations and Treasurer and Vice President of Finance for the Americas and Global Product Engines. Mr. Abernethy began his career with KPMG LLP and is a certified public accountant since 2017.
| Age | 44 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 12780 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 617 7600 |
| Web | https://www.neurocrine.com |
Neurocrine Biosciences Management Efficiency
The company has return on total asset (ROA) of 0.118 % which means that it generated a profit of $0.118 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1635 %, meaning that it created $0.1635 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2024. Return On Capital Employed is likely to rise to 0.10 in 2024. At this time, Neurocrine Biosciences' Fixed Asset Turnover is fairly stable compared to the past year. Return On Assets is likely to rise to 0.08 in 2024, whereas Intangibles To Total Assets are likely to drop 0.01 in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Todd MBA | Supernus Pharmaceuticals | N/A | |
| Jeff Coon | Dynavax Technologies | 61 | |
| Jennifer PharmD | Avadel Pharmaceuticals PLC | N/A | |
| Richard Kahr | Pacira BioSciences, | N/A | |
| Dan MBA | Amphastar P | N/A | |
| MBA MPA | Evotec SE ADR | 56 | |
| Sandra Coombs | Alkermes Plc | N/A | |
| Dennis McLoughlin | Pacira BioSciences, | 58 | |
| Stephen Schiavo | Alkermes Plc | N/A | |
| Ian Hunneyball | Evotec SE ADR | 74 | |
| Andrew Davis | Ironwood Pharmaceuticals | 38 | |
| Angie Woods | Avadel Pharmaceuticals PLC | N/A | |
| Blair Jackson | Alkermes Plc | 51 | |
| Gabriele Hansen | Evotec SE ADR | N/A | |
| James Marken | ANI Pharmaceuticals | 61 | |
| Susan Mesco | Pacira BioSciences, | N/A | |
| Shawn Cross | Pacira BioSciences, | 56 | |
| Kevin Esq | Supernus Pharmaceuticals | 62 | |
| Lauren Riker | Pacira BioSciences, | 45 | |
| Peter Norman | Alkermes Plc | N/A | |
| Ori Gutwerg | ANI Pharmaceuticals | 49 | |
Management Performance
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.12 |
Neurocrine Biosciences Leadership Team
Elected by the shareholders, the Neurocrine Biosciences' board of directors comprises two types of representatives: Neurocrine Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurocrine. The board's role is to monitor Neurocrine Biosciences' management team and ensure that shareholders' interests are well served. Neurocrine Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurocrine Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Cooke, Chief People Officer | ||
| Matthew Abernethy, Chief Officer | ||
| Eric Benevich, Chief Commercial Officer | ||
| Darin Lippoldt, Chief Legal Officer | ||
| Jude Onyia, Chief Officer | ||
| Dimitri Grigoriadis, Chief Research Officer | ||
| Kyle Gano, Chief Business Development Officer | ||
| Darin Esq, Chief Secretary | ||
| Jane Sorensen, Investor Relations Officer | ||
| Eiry MD, Chief Officer | ||
| David Boyer, Chief Officer | ||
| Kevin Gorman, CEO and President and Director | ||
| Matthew CPA, Chief Officer | ||
| Ingrid Delaet, Chief Officer | ||
| Christopher OBrien, Exclusive Consultant |
Neurocrine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neurocrine Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 11.75 B | ||||
| Shares Outstanding | 101.25 M | ||||
| Shares Owned By Insiders | 0.99 % | ||||
| Shares Owned By Institutions | 95.61 % | ||||
| Number Of Shares Shorted | 2.48 M | ||||
| Price To Earning | 202.90 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.